UnknownNot Applicable

Urin-based Point-of-Care Testing for Direct Oral Anticoagulants in Stroke Patients

Germany200 participantsStarted 2023-01-01

Plain-language summary

The goal of this study is to test a urine-based point-of-care testing device for direct oral anticoagulants in patients with stroke. The main questions are: * Can the test identify patients with direct oral anticoagulant intake? * Is there a time benefit of urine-based point-of-care testing compared to standard blood-based coagulation assessment? * Is the device feasible in the setting of acute stroke care?

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient age ≥18 years at the time of admission * Clinical diagnosis of ischemic or hemorrhagic stroke. * Treatmet at our certified stroke-unit, University Hospital Giessen. * Phase 1 only: Confirmed intake of a direct oral anticoagulant (DOAC) for at least 48 hours (test group) or no intake of a DOAC (control group for specificity determination) * Phase II only, anamnestic intake of DOAC or no information about OAC-intake. * Phase II only, presentation with 4.5 hours after onset. Exclusion Criteria (only Phase II): * Contraindications for intravenous thrombolysis other than intake of DOAC * large vessel occlusion with indication for immediate endovascular thrombectomy * chronic renal insufficiency with need for hemodialysis

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Time-benefit of urine-based POC-testing versus standard blood-based coagulation assessment

Timeframe: 24 hours

Trial details

NCT IDNCT06037200

SponsorUniversity of Giessen

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-06-30

Contact for this trial

Stefan Gerner, MD

+49-641/985-45301 stefan.gerner@neuro.med.uni-giessen.de

View on ClinicalTrials.gov More Stroke trials